MX359947B - EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. - Google Patents
EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.Info
- Publication number
- MX359947B MX359947B MX2013010507A MX2013010507A MX359947B MX 359947 B MX359947 B MX 359947B MX 2013010507 A MX2013010507 A MX 2013010507A MX 2013010507 A MX2013010507 A MX 2013010507A MX 359947 B MX359947 B MX 359947B
- Authority
- MX
- Mexico
- Prior art keywords
- interferon
- patient
- flu
- severity
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452807P | 2011-03-15 | 2011-03-15 | |
| US201161476930P | 2011-04-19 | 2011-04-19 | |
| PCT/US2012/029201 WO2012125809A1 (en) | 2011-03-15 | 2012-03-15 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010507A MX2013010507A (es) | 2014-04-30 |
| MX359947B true MX359947B (es) | 2018-10-17 |
Family
ID=46045072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010507A MX359947B (es) | 2011-03-15 | 2012-03-15 | EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US9198955B2 (enExample) |
| EP (1) | EP2686002B1 (enExample) |
| JP (2) | JP6279905B2 (enExample) |
| KR (1) | KR102050339B1 (enExample) |
| CN (1) | CN103702680A (enExample) |
| AU (1) | AU2012229104B2 (enExample) |
| BR (1) | BR112013023609A8 (enExample) |
| CA (1) | CA2846786C (enExample) |
| CY (1) | CY1120176T1 (enExample) |
| DK (1) | DK2686002T3 (enExample) |
| EA (1) | EA028448B1 (enExample) |
| ES (1) | ES2666850T3 (enExample) |
| HR (1) | HRP20180621T1 (enExample) |
| HU (1) | HUE036931T2 (enExample) |
| IL (1) | IL228425A (enExample) |
| LT (1) | LT2686002T (enExample) |
| MX (1) | MX359947B (enExample) |
| PL (1) | PL2686002T3 (enExample) |
| PT (1) | PT2686002T (enExample) |
| RS (1) | RS57175B1 (enExample) |
| SG (1) | SG193446A1 (enExample) |
| SI (1) | SI2686002T1 (enExample) |
| SM (1) | SMT201800221T1 (enExample) |
| WO (1) | WO2012125809A1 (enExample) |
| ZA (1) | ZA201306933B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2846786C (en) * | 2011-03-15 | 2022-05-17 | Biogen Idec Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
| EP3092305B1 (en) | 2014-01-09 | 2023-08-02 | Kyushu University, National University Corporation | Method of producing microglial cells |
| WO2018056584A1 (ko) | 2016-09-21 | 2018-03-29 | 삼성전자 주식회사 | 피부 상태 측정 방법 및 이를 위한 전자 장치 |
| WO2022069250A1 (en) * | 2020-09-30 | 2022-04-07 | Koninklijke Philips N.V. | Methods and systems for performing dose titration |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| WO1982002715A1 (fr) | 1981-02-04 | 1982-08-19 | Sugano Haruo | Gene d'interferon (beta)humain |
| US4695543A (en) | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
| CA1302320C (en) | 1984-06-11 | 1992-06-02 | Hideo Niwa | Expression of human cromosomal interferon-_ in animal cells |
| US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
| FI90990C (fi) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
| ATE78262T1 (de) | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | Hybrid-interferone. |
| US5641656A (en) | 1993-10-22 | 1997-06-24 | University Of Connecticut | Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them |
| DE69729880T3 (de) * | 1996-12-24 | 2012-05-10 | Biogen Idec Ma Inc. | Stabile flüssige interferon-zubereitungen |
| JP2001104482A (ja) * | 1999-10-07 | 2001-04-17 | Terumo Corp | ２室型プレフィルドシリンジ |
| US8932265B2 (en) * | 2003-01-30 | 2015-01-13 | Becton, Dickinson And Company | Holder with safety shield for a drug delivery device |
| US7731948B2 (en) * | 2004-06-01 | 2010-06-08 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| US20060089593A1 (en) * | 2004-10-26 | 2006-04-27 | Sergio Landau | Needle-free injection device for individual users |
| EP1923085A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
| US8071544B2 (en) * | 2006-12-18 | 2011-12-06 | Althea Technologies, Inc. | Crystallized recombinant human growth factor formulations |
| US9044378B2 (en) * | 2007-05-31 | 2015-06-02 | Safety Syringes, Inc. | Anti-needle stick safety device or system for use with drugs requiring reconstitution |
| JP5549048B2 (ja) * | 2007-08-16 | 2014-07-16 | 味の素株式会社 | 薬剤バイアルとプレフィルドシリンジの接続構造 |
| MX2011013722A (es) * | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
| CA2846786C (en) * | 2011-03-15 | 2022-05-17 | Biogen Idec Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
-
2012
- 2012-03-15 CA CA2846786A patent/CA2846786C/en active Active
- 2012-03-15 HU HUE12719487A patent/HUE036931T2/hu unknown
- 2012-03-15 WO PCT/US2012/029201 patent/WO2012125809A1/en not_active Ceased
- 2012-03-15 HR HRP20180621TT patent/HRP20180621T1/hr unknown
- 2012-03-15 KR KR1020137027053A patent/KR102050339B1/ko active Active
- 2012-03-15 US US13/421,197 patent/US9198955B2/en active Active
- 2012-03-15 ES ES12719487.6T patent/ES2666850T3/es active Active
- 2012-03-15 RS RS20180455A patent/RS57175B1/sr unknown
- 2012-03-15 DK DK12719487.6T patent/DK2686002T3/en active
- 2012-03-15 JP JP2013558168A patent/JP6279905B2/ja active Active
- 2012-03-15 CN CN201280019863.2A patent/CN103702680A/zh active Pending
- 2012-03-15 PL PL12719487T patent/PL2686002T3/pl unknown
- 2012-03-15 SM SM20180221T patent/SMT201800221T1/it unknown
- 2012-03-15 AU AU2012229104A patent/AU2012229104B2/en active Active
- 2012-03-15 SG SG2013069018A patent/SG193446A1/en unknown
- 2012-03-15 PT PT127194876T patent/PT2686002T/pt unknown
- 2012-03-15 LT LTEP12719487.6T patent/LT2686002T/lt unknown
- 2012-03-15 EP EP12719487.6A patent/EP2686002B1/en active Active
- 2012-03-15 SI SI201231281T patent/SI2686002T1/en unknown
- 2012-03-15 BR BR112013023609A patent/BR112013023609A8/pt not_active Application Discontinuation
- 2012-03-15 MX MX2013010507A patent/MX359947B/es active IP Right Grant
- 2012-03-15 EA EA201301024A patent/EA028448B1/ru unknown
-
2013
- 2013-09-12 ZA ZA2013/06933A patent/ZA201306933B/en unknown
- 2013-09-12 IL IL228425A patent/IL228425A/en active IP Right Grant
-
2015
- 2015-11-09 US US14/936,228 patent/US20160101157A1/en not_active Abandoned
-
2017
- 2017-09-05 JP JP2017170640A patent/JP6522069B2/ja active Active
- 2017-09-05 US US15/695,587 patent/US10500254B2/en active Active
-
2018
- 2018-04-23 CY CY20181100424T patent/CY1120176T1/el unknown
-
2019
- 2019-10-22 US US16/660,038 patent/US20200046804A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/827,282 patent/US20220280610A1/en not_active Abandoned
-
2025
- 2025-05-05 US US19/198,871 patent/US20250276042A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018067906A2 (pt) | métodos de tratamento de depressão usando antagonistas do receptor de orexina-2 | |
| IN2014MN00333A (enExample) | ||
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| BR112015027297A8 (pt) | administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| NI201400104A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| MX369259B (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| UY35190A (es) | Composición farmacéutica en forma de una suspensión oral que comprende una fracción flavonoica y goma de xantano | |
| BR112015010651A2 (pt) | composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos | |
| HUE036931T2 (hu) | Az interferon intramuszkuláris beadásakor jelentkezõ influenzaszerû tünetek csökkentésének módszere egy gyors titrálási dózisemelõ kezelés alkalmazásával | |
| BR112014015314A8 (pt) | composição farmacêutica não entérica compreendendo crofelemer | |
| EA201300096A1 (ru) | Лекарственный препарат, обладающий антибактериальным, противоязвенным и иммуномодулирующим действием | |
| CO2018013792A2 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo | |
| MX2015009681A (es) | Un medicamento combinado que comprende finilefrina y paracetamol. | |
| DK2609926T3 (da) | Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat | |
| CL2013003671A1 (es) | Composicion y combinacion farmaceutica que comprende ketorolaco y meloxicam; proceso para preparar la composicion; uso en el tratamiento de la inflamacion y el dolor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: PFIZER, INC. |
|
| GB | Transfer or rights |
Owner name: BIOGEN MA INC. |
|
| FG | Grant or registration |